Business Wire

ONWARD Announces New Board Appointment

Share

ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announces the appointment of Kristina Dziekan to its Board of Directors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220613005579/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Kristina Dziekan (Photo: Business Wire)

“Kristina strengthens our Board, bringing judgment and expertise needed for our next phase of growth,” said Dave Marver, CEO of ONWARD. “She has extensive experience in market access and reimbursement across global markets, and specific industry experience in neuromodulation. All of this will be important as we prepare to commercialize our breakthrough therapies in the US and Europe starting next year.”

Ms. Dziekan is currently Head of Market Access, Government Affairs, and Tendering for Alcon’s Surgical Division in Europe. She previously served as Senior Global Reimbursement and Health Economics Director for Medtronic Neuromodulation and was also Health Outcomes Manager for GlaxoSmithKline in the UK and parts of Asia.

She earned an MSc in Health Policy, Planning, and Financing from the London School of Economics, an MA in International Economics and European Studies from Johns Hopkins University, a BA in Philosophy, Politics, and Economics from Oxford University, and a Vordiplom in Business Administration and Economics from Georg August University.

Ms. Dziekan was appointed to a four-year term during ONWARD’s Annual General Meeting, held 10 June 2022 in Amsterdam, the Netherlands.

About ONWARD

ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries. ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable (ARCIM) or external (ARCEX) systems, is designed to deliver targeted, programmed spinal cord stimulation to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. ONWARD has received three Breakthrough Device Designations from the FDA encompassing both ARCIM and ARCEX. The Company’s first FDA pivotal trial, called Up-LIFT, completed enrollment in December 2021 with 65 subjects worldwide. It recently completed first-in-human use of its ARCIM neurostimulator in May 2022.

ONWARD is headquartered at the High Tech Campus in Eindhoven, the Netherlands. It maintains a significant team in Lausanne, Switzerland and has a growing U.S. presence in Boston, Massachusetts, USA. For additional information about the Company, please visit ONWD.com. To access our 2022 Financial Calendar, please visit IR.ONWD.com.

Disclaimer

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Media Enquiries:
Andy Dolan
media@onwd.com
+1.508.649.8466

For Investor Enquiries:
investors@onwd.com
For Company Enquiries:
info@onwd.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Landmark Study Reveals New Technology from DeBogy Molecular Significantly Reduces the Bacteria and Deadly Infection that Can Occur Following a Surgical Implant27.6.2022 15:15:00 CEST | Press release

DeBogy Molecular, Inc, a biotech startup that specializes in antimicrobial surface modification, today announced the findings of a landmark in vivo research study that affirms the effectiveness and safety of their new technology to kill the dangerous bacteria that proliferates on the surface of a medical implant following surgery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220626005067/en/ Wayne Gattinella CEO, DeBogy Molecular, Inc (Photo: Business Wire) Infection resulting from bacterial biofilm that forms on the surface of a medical implant represents one of the most serious complications that can follow orthopedic surgery or the implantation of a medical device. Implant related infections account for over half of the 2 million yearly healthcare-associated infections in the U.S., at a cost of over $27 billion dollars annually. A preclinical research study was conducted by Vivexia, an independent Clinical Research Orga

NielsenIQ Accelerates Expansion of Global Retail Strategy with Addition of Retail Lab Leader, Dawn E. Norvell27.6.2022 15:00:00 CEST | Press release

NielsenIQ has strengthened its leading global retail practice with the addition of Dawn E. Norvell as Global Head of the newly formed NielsenIQ Retail Lab. In her new role, Norvell will lead a progressive team created to better identify retail client needs, design solutions, and enable retailers to use NielsenIQ's full suite of products to help drive their business. Norvell will build a sales and commercial management strategy designed to expand NielsenIQ's retail analytics focus and enable growth within the business unit. “The NielsenIQ Retail Lab is an important part of our global retail strategy & company success, and Dawn’s industry-leading knowledge and background in the global marketplace gives a rare viewpoint of the current retail climate,” said David Johnson, Global President of Retail at NielsenIQ. “Her extensive first-hand experience will enhance our broad range of go-to-market client offerings and add significant depth to our retail team. We are thrilled that NielsenIQ cont

Work for Humankind: World of Possibilities Opens Up for Remote Island with Lenovo Technology27.6.2022 15:00:00 CEST | Press release

As part of its landmark partnership with Island Conservation and the Robinson Crusoe Island community, Lenovo reveals the next stage of its Work for Humankind project: critical pieces of smarter technology installed throughout the island will become permanent fixtures to leave a lasting legacy and stronger connectivity on an island that’s home to one of the world’s most diverse ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220627005008/en/ Work for Humankind volunteers working remotely from Lenovo’s technology workspace on Robinson Crusoe Island, Chile (Photo: Business Wire) Bridging the digital divide, a previously isolated island of 900 people will now remain connected to the world through Lenovo technology to open new possibilities for tourism, trade, employment, and education, increasing its environmental and economic resilience. For the first time ever, this remote island community has self-determined, equi

The Minister of Trade and Industry Launches the Norwegian Government's Battery Strategy at FREYR Battery in Mo i Rana27.6.2022 13:39:00 CEST | Press release

FREYR Battery (NYSE: FREY) (“FREYR”), a developer of clean, next-generation battery cell production capacity, welcomes the Minister of Trade and Industry to launch the Norwegian Government's National Battery Strategy at FREYR Battery's giga giga factory location in Mo i Rana, Northern Norway. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220627005371/en/ "Sentraltomta" inside Mo industrial Park (Photo: Business Wire) This was announced at the Norwegian government’s webpages Monday morning 27th June Norwegian time: https://www.regjeringen.no/no/aktuelt/naringsministeren-lanserer-regjeringens-batteristrategi/id2920877/ FREYR Battery CEO, Tom Einar Jensen, says: “We are very proud that the Norwegian Government has chosen FREYR Battery’s giga factory location in Mo i Rana, as the historic place to launch Norway's National Battery Strategy. We warmly welcome the Minister of Trade and Industry, and experience this as a strong con

Time Manufacturing Company Acquires France Elévateur27.6.2022 12:00:00 CEST | Press release

H.I.G. Capital ("H.I.G."), a leading global alternative investment firm with over $49 billion of equity capital under management, is pleased to announce that its portfolio company, Time Manufacturing Holdings, LLC (“Time Manufacturing” or the “Company”), a leading, global provider of vehicle-mounted aerial lifts, has acquired France Elévateur (“FE Group”). The pairing of the two companies, who share a mutual dedication to quality and safety, strengthens the combined platform’s global manufacturing capabilities while enhancing value to customers through a broader portfolio of complementary products and services. Founded in 1984 and headquartered in Flavigny, France, France Elévateur is a leading manufacturer of vehicle-mounted aerial platforms for customers in various trades including public lighting, electric utility, roofing, telecommunications, rail networks, and other fields requiring access solutions. Through its two manufacturing sites in France and Spain and its footprint of 15 s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom